Media stories about Cumberland Pharmaceuticals (NASDAQ:CPIX) have been trending somewhat positive recently, according to Accern. The research firm identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cumberland Pharmaceuticals earned a news impact score of 0.21 on Accern’s scale. Accern also assigned news headlines about the specialty pharmaceutical company an impact score of 46.2409547442987 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Shares of Cumberland Pharmaceuticals (NASDAQ:CPIX) traded down 0.58% on Thursday, reaching $6.87. 3,618 shares of the company’s stock were exchanged. The stock’s market cap is $110.15 million. The company’s 50 day moving average price is $6.96 and its 200-day moving average price is $6.38. Cumberland Pharmaceuticals has a 52-week low of $4.40 and a 52-week high of $7.49.
Cumberland Pharmaceuticals (NASDAQ:CPIX) last posted its quarterly earnings results on Monday, May 15th. The specialty pharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter. Cumberland Pharmaceuticals had a negative net margin of 5.63% and a positive return on equity of 1.93%. The business had revenue of $9.64 million during the quarter. Equities analysts forecast that Cumberland Pharmaceuticals will post $0.09 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact Cumberland Pharmaceuticals (CPIX) Stock Price” was originally reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this piece on another website, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be accessed at https://sportsperspectives.com/2017/07/20/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-cumberland-pharmaceuticals-cpix-stock-price.html.
About Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Inc (Cumberland) is a specialty pharmaceutical company. The Company is focused on the acquisition, development and commercialization of branded prescription products. The Company operates through specialty pharmaceutical products segment. The Company’s product portfolio includes Acetadote (acetylcysteine) Injection for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) Injection for the treatment of pain and fever; Kristalose (lactulose) for Oral Solution for the treatment of chronic and acute constipation; Omeclamox-Pak, (omeprazole, clarithromycin, amoxicillin) for the treatment of Helicobacter pylori (H.
Receive News & Ratings for Cumberland Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.